PMID- 15464128
OWN - NLM
STAT- MEDLINE
DCOM- 20041220
LR  - 20131121
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 47 Suppl 1
DP  - 2004
TI  - The methamphetamine experience: a NIDA partnership.
PG  - 92-100
AB  - The neurotoxic properties of the amphetamines such as methamphetamine (METH) were 
      originally described about the time of the National Institute on Drug Abuse's 
      organization, in the early 1970s. It required more than 20 years to confirm these 
      neurotoxic properties in humans. Much like Parkinson's disease, multiple 
      high-dose administration of METH somewhat selectively damages the nigrostriatal 
      dopamine (DA) projection of the brain. This effect appears to be related to the 
      intracellular accumulation of cytosolic DA and its ability to oxidize into 
      reactive oxygen species. Both the dopamine plasmalemmal transporter and the 
      vesicular monoamine transporter-2 seem to play critical roles in this 
      neurotoxicity. METH and related analogs such as methylenedioxymethamphetamine 
      (MDMA) can also damage selective CNS serotonin neurons. The mechanism of the 
      serotonergic neurotoxicity is not as well characterized, but also appears to be 
      related to the formation of reactive oxygen species and monoamine transporters. 
      Studies examining the pharmacological and neurotoxicological properties of the 
      amphetamines have helped to elucidate some critical features of monoamine 
      regulations as well as helped to improve our understanding of the processes 
      associated with degenerative disorders such as Parkinson's disease.
FAU - Hanson, Glen R
AU  - Hanson GR
AD  - Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 
      East, Skaggs Hall, Room 112, Salt Lake City, UT 84112, USA. 
      glen.hanson@hsc.utah.edu
FAU - Rau, Kristi S
AU  - Rau KS
FAU - Fleckenstein, Annette E
AU  - Fleckenstein AE
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 333DO1RDJY (Serotonin)
RN  - 44RAL3456C (Methamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Amphetamine-Related Disorders/*physiopathology
MH  - Animals
MH  - *Central Nervous System Stimulants
MH  - Dopamine/physiology
MH  - Dopamine Plasma Membrane Transport Proteins
MH  - Humans
MH  - Membrane Glycoproteins/metabolism
MH  - Membrane Transport Proteins/metabolism
MH  - *Methamphetamine
MH  - National Institutes of Health (U.S.)
MH  - Nerve Tissue Proteins/metabolism
MH  - Neurotoxicity Syndromes/physiopathology
MH  - Serotonin/physiology
MH  - United States
RF  - 59
EDAT- 2004/10/07 09:00
MHDA- 2004/12/21 09:00
CRDT- 2004/10/07 09:00
PHST- 2004/04/14 00:00 [received]
PHST- 2004/05/19 00:00 [revised]
PHST- 2004/05/28 00:00 [accepted]
PHST- 2004/10/07 09:00 [pubmed]
PHST- 2004/12/21 09:00 [medline]
PHST- 2004/10/07 09:00 [entrez]
AID - S0028390804001583 [pii]
AID - 10.1016/j.neuropharm.2004.06.004 [doi]
PST - ppublish
SO  - Neuropharmacology. 2004;47 Suppl 1:92-100. doi: 10.1016/j.neuropharm.2004.06.004.